Novel biomarkers for pulmonary arterial hypertension.
Novel biomarkers for pulmonary arterial hypertension.
复制标题
DOI：
10.1186/s12931-016-0396-6
复制
发表时间：
2016-07-20
影响因子：
5.8
通讯作者：
Umar S
中科院分区：
文献类型：
--
作者：
Anwar A;Ruffenach G;Mahajan A;Eghbali M;Umar S
肺动脉高压是一种以肺动脉压升高导致右心室肥厚和衰竭为特征的致命疾病。确证性金标准试验是有创右心导管插入术。通过经胸超声心动图测量肺动脉收缩压来监测病程。需要一种简单的无创检测来频繁监测患者。寻找一种可以通过简单测试检测到的新型生物标志物正在进行中，许多不同的选择正在研究中。在这里，我们回顾了一些新的和独特的潜在肺动脉高压生物标志物的临床前选择。这些生物标志物可根据其与内皮细胞功能障碍、炎症、表观遗传学、心功能、氧化应激、代谢、细胞外基质和呼出冷凝水中挥发性化合物的关联进行大致分类。一种可以在血液、尿液或呼吸凝聚物中检测到并与疾病严重程度、进展和治疗反应相关的生物标志物可能会显著降低成本并改善患者预后。
Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The disease course is monitored by pulmonary artery systolic pressure measurement via transthoracic echocardiography. A simple non-invasive test to frequently monitor the patients is much needed. Search for a novel biomarker that can be detected by a simple test is ongoing and many different options are being studied. Here we review some of the new and unique pre-clinical options for potential pulmonary hypertension biomarkers. These biomarkers can be broadly categorized based on their association with endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, metabolism,extracellular matrix, and volatile compounds in exhaled breath condensate. A biomarker that can be detected in blood, urine or breath condensate and correlates with disease severity, progression and response to therapy may result in significant cost reduction and improved patient outcomes.